Literature DB >> 16647099

Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines.

Rafik Fayzulin1, Frank Scholle, Olga Petrakova, Ilya Frolov, Peter W Mason.   

Abstract

A stable cell system for high-efficiency packaging of West Nile virus (WNV) subgenomic replicons into virus-like particles (VLPs) was developed. VLPs could be propagated on these packaging cells and produced infectious foci similar to foci produced by WNV. Focus size correlated with the replicative capacity of WNV replicons, indicating that genome copy number, rather than amount of trans-complementing structural proteins, was rate-limiting in packaging of VLPs. Comparison of VLP production from replicon genomes encoding partial or complete C genes indicated that portions of C downstream of the cyclization sequence could improve genome replication or that cis expression of C could enhance packaging. Interestingly, a rapid loss of replicon-encoded reporter gene activity was detected within two serial passages of reporter gene-containing VLPs. The loss of reporter activity correlated with gene deletion and better VLP growth, indicating a powerful selection pressure for WNV genomes lacking reporter genes.

Entities:  

Mesh:

Year:  2006        PMID: 16647099     DOI: 10.1016/j.virol.2006.02.036

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation.

Authors:  Camilo Ansarah-Sobrinho; Steevenson Nelson; Christiane A Jost; Stephen S Whitehead; Theodore C Pierson
Journal:  Virology       Date:  2008-09-17       Impact factor: 3.616

2.  Subcapsular sinus macrophages limit dissemination of West Nile virus particles after inoculation but are not essential for the development of West Nile virus-specific T cell responses.

Authors:  Evandro R Winkelmann; Douglas G Widman; Jingya Xia; Alison J Johnson; Nico van Rooijen; Peter W Mason; Nigel Bourne; Gregg N Milligan
Journal:  Virology       Date:  2014-01-10       Impact factor: 3.616

3.  Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine.

Authors:  Michelle H Nelson; Evandro Winkelmann; Yinghong Ma; Jingya Xia; Peter W Mason; Nigel Bourne; Gregg N Milligan
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

4.  Production of pseudoinfectious yellow fever virus with a two-component genome.

Authors:  Alexandr V Shustov; Peter W Mason; Ilya Frolov
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

5.  Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2.

Authors:  Ryosuke Suzuki; Evandro R Winkelmann; Peter W Mason
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction.

Authors:  Jason R Wilson; Paola Florez de Sessions; Megan A Leon; Frank Scholle
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

7.  Extension of flavivirus protein C differentially affects early RNA synthesis and growth in mammalian and arthropod host cells.

Authors:  Sabrina Schrauf; Christian W Mandl; Lesley Bell-Sakyi; Tim Skern
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

Review 8.  Flavivirus methyltransferase: a novel antiviral target.

Authors:  Hongping Dong; Bo Zhang; Pei-Yong Shi
Journal:  Antiviral Res       Date:  2008-06-05       Impact factor: 5.970

9.  Engineering the Japanese encephalitis virus RNA genome for the expression of foreign genes of various sizes: implications for packaging capacity and RNA replication efficiency.

Authors:  Sang-Im Yun; Yu-Jeong Choi; Xiao-Fang Yu; Jae-Young Song; Young-Hak Shin; Young-Ran Ju; Seok-Yong Kim; Young-Min Lee
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

10.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.